AlphaCentric Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

AlphaCentric Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,400	Closed	-$1.63M	–	235
2023 Q1	$1.63M	Hold	3,400	–	–	1.12%	21
2022 Q4	$1.43M	Buy	3,400 +1,700	+100%	+$686K	1.41%	16
2022 Q3	$709K	Buy	+1,700	New	+$848K	0.73%	47
2021 Q4	–	Sell	-106	Closed	-$79K	–	227
2021 Q3	$79K	Sell	106 -65	-38%	-$48.7K	0.02%	180
2021 Q2	$110K	Buy	171 +14	+9%	+$8.52K	0.03%	167
2021 Q1	$90K	Sell	157 -3	-2%	-$1.78K	0.03%	165
2020 Q4	$93K	Buy	160 +96	+150%	+$54.7K	0.04%	143
2020 Q3	$33K	Hold	64	–	–	0.02%	128
2020 Q2	$29K	Buy	+64	New	+$28.2K	0.02%	106

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

AlphaCentric Advisors's BIO Position: Q2 2023 in Review

AlphaCentric Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 3,400 shares — an estimated $1.63M sold.

AlphaCentric Advisors first reported a position in BIO in Q2 2020 and held it in 9 quarters. The position peaked at $1.63M in Q1 2023. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

AlphaCentric Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
AlphaCentric Advisors sold 3,400 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $1.63M.
AlphaCentric Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 9 quarters.
AlphaCentric Advisors's Bio-Rad Laboratories Class A position peaked at $1.63M in Q1 2023.
469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.